Lilly Buys Psychedelic Startup for $2.8B | Business and Finance News

Eli Lilly is betting big on mental health by snapping up AtaiBeckley for $2.8 billion, with another $1 billion on the table if their psychedelic drug hits targets. The deal, set to close by Q3, could reshape treatment for treatment-resistant depression with BPL-003 — a synthetic DMT nasal spray showing months-long relief in trials and earning FDA fast-track status. AtaiBeckley’s stock soared 30% on the news, and this isn’t just a one-off: Lilly’s on a buying spree, expanding into vaccines and psychedelics to diversify beyond diabetes and weight loss meds. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7bcb3d484d7c8026